This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hostetter TH and Ibrahim HN (2003) Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 14: 2395–2401
Bomback AS and Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3: 486–492
Bomback AS et al. (2008) Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51: 199–211
Monrad SU et al. (2008) The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther 10: R5
Bochud M et al. (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48: 239–245
de Paula RB et al. (2004) Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43: 41–47
Nagase M et al. (2006) Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17: 3438–3446
Pérez-Rojas JM et al. (2005) Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 289: F1020–F1030
Pérez-Rojas J et al. (2007) Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292: F131–F139
Mejía-Vilet JM et al. (2007) Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293: F78–F86
Sato A and Saruta T (2004) Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 27: 303–310
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bomback, A., Kshirsagar, A. & Klemmer, P. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?. Nat Rev Nephrol 5, 74–75 (2009). https://doi.org/10.1038/ncpneph1004
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph1004
This article is cited by
-
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists
Diabetologia (2024)
-
Aldosterone: effects on the kidney and cardiovascular system
Nature Reviews Nephrology (2010)
-
Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination
American Journal of Hypertension (2009)